Menu
← Oncology Approval Tracker
FDA DECISION ·
Rasonque
daraxonrasib · Revolution Medicines
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic pancreatic adenocarcinoma who have received at least one systemic therapy or are ineligible for multiagent systemic therapy.
SUPPORTING DATA
Evidence behind the decision
- Study
- RASolute 302 randomized 500 patients after progression following one line to daraxonrasib or physician-choice chemotherapy.
- Key result
- In the overall population, median overall survival was 13.2 vs 6.7 months (hazard ratio 0.40, 95% CI, 0.30–0.53). Median progression-free survival was 7.2 vs 3.6 months.
- Safety to report
- FDA lists skin and soft-tissue toxicity, oral toxicity, diarrhea, gastrointestinal perforation and ILD or pneumonitis among the warnings.
- Evidence limits
- The randomized study enrolled patients with progression after one prior line. The label also includes adults who are ineligible for multiagent therapy.
LAMPGEN ANALYSIS
Why it matters
RASolute 302 reported a survival benefit against physician-choice chemotherapy after one prior treatment line. The approved use also includes adults ineligible for multiagent therapy, a broader group than the pivotal study enrolled.
What research teams should watch
Preserve line-of-therapy and treatment-fitness documentation. For future trials, the new option can affect the relevance of a comparator and the therapies patients receive before enrollment.
PRIMARY RECORDS